Appendix Table E13. Phenotypic test details in studies assessing the predictive ability of LTA in patients with ischemic heart, cerebrovascular and peripheral vascular disease

| **Author, year [ref]**  **UID**  **Country**  **Study Name** | **Test/Device name**  **Device category Device name & manufacturer\*** | **Agonist used** | **Sample Collection and Procurement**  **Anticoagulant used**  **Interval between clopidogrel doses and blood sampling (in days)**  **Interval between sampling and testing (in days):** | **Grouping of Phenotypes [Definition]** | **Rational for the grouping of phenotypes reported (Yes/No)**  **[short description]** | **Frequency of phenotypes** |
| --- | --- | --- | --- | --- | --- | --- |
| Reny, 2012  22615340  France and Switzerland  ADRIE | 8-channel aggregometer (TA-8V, SD Medical, Heillecourt,  France) | ADP 5 and 20 µmol/L | Blood samples collected after antiplatelet therapy intake  0.105 mol/L sodium citrate (1  vol/9 vol)  3 hrs  NR | ≥55% with ADP  20 µmol/L  ≥42% with ADP 5 µmol/L | Based on ROC curve | ≥55%:445  <55%: 204  ≥42%: 490  <42%: 159 |